-
Mashup Score: 0Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications - 1 year(s) ago
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the key differences between the International Consensus Classification (ICC) and World…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
In this video, Cyrus Khandanpour MD, PhD, University Hospital of Schleswig-Holstein, Lübeck, Germany, discusses research into the germline variant GFI1-36N…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ISAL2023 | @c_khandanpour of @UniLuebeck discusses research into the germline variant GFI1-36N and its impact on patient response to therapy in AML: 🎥 https://t.co/byMk1vryDS #AMLsm #LeuSM #HemOnc
-
-
Mashup Score: 0Novel mitochondrial targets being explored in AML & strategies to overcome resistance to venetoclax - 1 year(s) ago
In this video, Michael Andreeff, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses mechanisms of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about novel mitochondrial targets being explored in AML & strategies to overcome resistance to venetoclax in our interview with Michael Andreeff (@MDAndersonNews): 🎥 https://t.co/YqfQ2wVhco #AMLsm #LeuSM #HemOnc #ISAL2023
-
-
Mashup Score: 0
Hi, I’m Charlie Craddock from Birmingham, UK, and I’m with my great colleague and friend Chris Hourigan from NIH in the United States. And we’re at the ISAL AML meeting. So Chris, a lot of the talk at this meeting is about the emerging and increasingly important role of transplant in the management of fit adults with AML. And there’s a lot of thought about how we improve transplant outcomes. And…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Be sure to tune in to this great discussion with experts Charles Craddock & Christopher Hourigan, filmed at #ISAL2023. Topics covered: ➡️ Improving transplant outcomes in AML ➡️ The pre-MEASURE study ➡️ The value of pre-transplant MRD 🎥: https://t.co/Us3ifgIXdV #AMLsm https://t.co/bq61BsYRNy
-
-
Mashup Score: 0
In this video, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the value of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ISAL2023 | @fravandi1 of @MDAndersonNews highlights the value of moving novel agents into the frontline setting when treating patients with ALL: 👉 https://t.co/K1N7pJw5Gh 👈 #LeuSM #ALLsm #HemOnc #ImmunoOnc
-
-
Mashup Score: 1The impact of CEBPA mutations & insights into the gene regulatory network of CEBPA-double mutant AML - 1 year(s) ago
Constanze Bonifer, PhD, University of Birmingham, Birmingham, UK, shares some insights into the role of CEBPA in the pathology of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Constanze Bonifer (@unibirmingham) shares some insights into the role of CEBPA in AML and the gene regulatory network of CEBPA-double mutant AML: ➡️ https://t.co/MN0PC3Bx4O #ISAL2023 #HemOnc #AMLsm #LeuSM
-
-
Mashup Score: 2
Inna Shaforostova, MD, University Hospital Münster (UKM), Münster, Germany, discusses a retrospective study which evaluated the clinical and prognostic significance…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Inna Shaforostova (@UK_Muenster) discusses the results of a retrospective study which evaluated the clinical & prognostic significance of aberrant T-cell marker expression in AML. Watch here: 🎥 https://t.co/ErUUAxhOHJ #AMLsm #LeuSM #HemOnc #ISAL2023
-
-
Mashup Score: 2
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the importance of addressing leukemic transformation (LT) in myelodysplastic syndromes (MDS),…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ISAL2023 | David Sallman (@MoffittNews) discusses the importance of addressing leukemic transformation in MDS & novel approaches being explored for patients: 👉 https://t.co/2ZmsgbbVKp 👈 #LeuSM #AMLsm #MDSsm #HemOnc
-
-
Mashup Score: 0
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses chemotherapy and transplant-free regimens in Philadelphia chromosome positive (Ph+) acute…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tune in to our exclusive interview with Robin Foà (@SapienzaRoma), who shares some insights into the current status of chemotherapy-free regimens in Ph+ ALL: 🎥 https://t.co/lvwGWpZVs4 #ISAL2023 #LeuSM #ALLsm #HemOnc #ImmunoOnc
-
-
Mashup Score: 1Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax - 1 year(s) ago
In this video, Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses the results of a multicenter study which investigated the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ISAL2023 | @GarciazSylvain discusses a study which evaluated the long-term survival of patients with AML who discontinued aza-ven due to poor tolerance: 👉 https://t.co/xL0P8xCAVc 👈 #AMLsm #LeuSM #HemOnc
-
Richard Stone (@DanaFarber) outlines key differences and updates in the ICC, WHO & ELN risk classifications for AML. Find out more below: 🎥: https://t.co/pvIWwq2lwC #ISAL2023 #AMLsm #LeuSM #HemOnc